Literature DB >> 16108961

Treatment persistency with rivastigmine and donepezil in a large state medicaid program.

Gurkirpal Singh, Simu K Thomas, Steve Arcona, Vijayabharathi Lingala, Alka Mithal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16108961     DOI： 10.1111/j.1532-5415.2005.53384_9.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  16 in total

1.  A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.

Authors:  Virginie Gardette; Maryse Lapeyre-Mestre; Antoine Piau; Adeline Gallini; Christelle Cantet; Jean-Louis Montastruc; Bruno Vellas; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

2.  Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.

Authors:  Virginie Gardette; Sandrine Andrieu; Maryse Lapeyre-Mestre; Nicola Coley; Christelle Cantet; Pierre-Jean Ousset; Alain Grand; Jean-Louis Monstastruc; Bruno Vellas
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

3.  Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.

Authors:  Anat Fisher; Greg Carney; Ken Bassett; Colin R Dormuth
Journal:  Drugs Aging       Date:  2017-03       Impact factor: 3.923

4.  Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.

Authors:  Noll L Campbell; Anthony J Perkins; Sujuan Gao; Todd C Skaar; Lang Li; Hugh C Hendrie; Nicole Fowler; Christopher M Callahan; Malaz A Boustani
Journal:  J Am Geriatr Soc       Date:  2017-03-14       Impact factor: 5.562

Review 5.  Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Authors:  Colleen J Maxwell; Kathryn Stock; Dallas Seitz; Nathan Herrmann
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

6.  Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.

Authors:  Carl H Sadowsky; George T Grossberg; Monique Somogyi; Xiangyi Meng
Journal:  Prim Care Companion CNS Disord       Date:  2011

7.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

8.  A population-based study of dosing and persistence with anti-dementia medications.

Authors:  Linda Brewer; Kathleen Bennett; Cora McGreevy; David Williams
Journal:  Eur J Clin Pharmacol       Date:  2013-02-27       Impact factor: 2.953

Review 9.  Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease.

Authors:  Nazem Bassil; George T Grossberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.

Authors:  Carolyn T Thorpe; Nicole R Fowler; Katherine Harrigan; Xinhua Zhao; Yihuang Kang; Joseph T Hanlon; Walid F Gellad; Loren J Schleiden; Joshua M Thorpe
Journal:  J Am Geriatr Soc       Date:  2016-08-22       Impact factor: 5.562
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.